More positive data for Eli Lilly’s (NYSE: LLY) weight loss candidate tirzepatide will boost interest in the product, as the US regulator warns of supply shortages at certain doses.
While currently approved for diabetes and marketed in this indication as Mounjaro, the upswing in demand is likely due to off-label prescribing, a factor which has also affected Novo Nordisk’s (NOV: N) rival GLP-1 agonist.
Novo Nordisk’s semaglutide has long been marketed for diabetes under the Ozempic brand, with an obesity-targeting formulation, labeled Wegovy, subsequently gaining approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze